Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma

Sponsor
Qianfoshan Hospital
Study ID
NCT07828327
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • ABPA
  • Allergic Bronchopulmonary Aspergillosis
  • Severe Eosinophilic Asthma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

An open-label study will evaluate effects of Depemokimab in the treatment of severe eosinophilic asthma in patients with allergic bronchopulmonary aspergillosis

Key Dates

First listed
Sep 18, 2026
Start date
Nov 1, 2026
Status verified
Sep 2026
Primary completion
Feb 28, 2027
Completion
Aug 31, 2027

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    Depemokimab treatment will be given by injections administered every 6 months.

Primary Outcome Measure

Number of steroid requiring exacerbations [ Time Frame: 26 weeks ]

Central Contacts

Related Studies